Goldman Sachs analyst Lizzie Dove ... possible by our math.” The analyst is most looking forward to Royal Caribbean’s Investor Day presentation and new long-term targets.

Goldman Sachs has ended a ban on underwriting companies with all-White, all-male boards, becoming the latest corporate giant ...

Technologies (NASDAQ: DVAX) fell 6% Tuesday after Goldman Sachs issued a rare "sell" rating on the biopharmaceutical company, ...

The leadership shake-up will see Goldman Sachs’s management committee grow to 39; the group of senior executives helps to steer the firm’s strategy and policy. Wells Fargo analyst Mike Mayo ...

Keefe, Bruyette & Woods analyst David Konrad reiterated an Outperform rating on the shares of Goldman Sachs Group Inc (NYSE ... UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ...

From Westpac’s Anthony Miller to Commonwealth Bank’s Andrew Hinchliff, the Wall Street giant is well represented on ...

Goldman Sachs analyst warns 340B reforms could ... as potential cost-saving measures by the new administration. Overall, for the 340B program, the analyst sees potential policy/legal outcomes ...

Goldman Sachs analyst Matthew Sykes double downgraded Cytek Biosciences (CTKB) to Sell from Buy with a price target of $4.50, down from $7. The ...